Dabigatran Can Safely Be Reversed in Patients with Renal Dysfunction

In an observational study, idarucizumab completely and safely reversed dabigatran across the spectrum of renal impairment.

Reversal of direct oral anticoagulants remains an active area of investigation. Idarucizumab, a humanized monoclonal antibody against dabigatran, completely reversed the anticoagulant effects of dabigatran in the manufacturer-funded, prospective, cohort RE-VERSE AD study of patients requiring drug reversal for life-threatening bleeding or surgical interventions (NEJM JW Oncol Hematol Oct 2017 and N Engl J Med 2017; 377:431). In this re-analysis, investigators studied how baseline renal function affected dabigatran reversal and clinical outcomes.

In the study, all 503 participants received a fixed 5-g dose of idarucizumab; 381 patients had renal impairment (creatinine clearance, <80 mL/minute), including 91 with severe renal impairment (creat…

Reviewing Author

Fatima Rodriguez, MD, MPH, FACC, FAHA

Disclosures

Consultant/Advisory BoardNovoNordisk; HealthPals; Novartis; Amgen

EquityHealthPals; Carta

Grant/Research SupportNational Institutes of Health/National Heart, Lung, and Blood Institute; American Heart Association–Robert Wood Johnson Foundation

Editorial BoardsCardiology and Therapy